NMD4C Launch Canadian Neuromuscular Clinical Trial Database
The NMD4C are excited to launch the The Canadian Neuromuscular Clinical Trial Database to provide a comprehensive and reliable landscape of Canadian neuromuscular clinical trials. The trial database is an initiative of the NMD4C Clinical Trial Network (CTN) created in collaboration with Canadian neuromuscular clinical trial site teams. Monthly updates are provided by clinical research coordinators working at Canadian trial sites, ensuring the most current information is always available.
The Canadian Neuromuscular Clinical Trial Database has been designed to meet the needs of Canadian neuromuscular trial community stakeholders.
- Providing accurate and up-to-date information: Our database provides reliable details about recruiting and not yet recruiting neuromuscular clinical trials, including clinical trial site locations and contact information.
- Fostering collaboration: Enables investigators to identify other sites conducting the same trial at different locations, fostering collaboration to address challenges and share best practices,
- Streamlining patient referral: Can be used as a tool to facilitate patient referral to appropriate clinical trials and/or clinical sites.
The database will continue to be updated and expanded. If you have any questions about the Canadian Neuromuscular Clinical Trial Database or would like to add your site to our list, please contact CTN manager Dr. Maria Masnata.
The NMD4C CTN is led by Dr. Craig Campbell, Dr. Jean Mah, and Dr. Kerri Schellenberg, with the objectives of increasing the number of clinical trials in Canada, enhance Canadian sites’ trial capacity, and support a cohesive network of clinician researchers and their teams.
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.